Last reviewed · How we verify
nitrendipine + hydrochlorothiazide, if necessary
At a glance
| Generic name | nitrendipine + hydrochlorothiazide, if necessary |
|---|---|
| Sponsor | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Isolated Systolic Hypertension in the Elderly and Very Elderly (PHASE3)
- Systolic Hypertension in Europe Placebo-Controlled Trial (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: